2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.115 Christina Baik NACLC Abstract

PP01.115 Christina Baik NACLC Abstract

Pdf Summary

A study analyzed the real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (NSCLC) and HER2 mutations. The study used data from the Flatiron Health-Foundation Medicine clinico-genomic database in the US. Among 11,794 adults diagnosed with advanced NSCLC between 2015 and 2021, 550 had a HER2 mutation, representing a prevalence of 4.7%. The median age at diagnosis was 69.2 years. Among the HER2 mutation types, the tyrosine kinase domain (TKD) mutation was found in 1.7% of patients, while non-TKD mutations were found in 2.9% of patients. Patients with TKD mutations tended to be female and never-smokers compared to patients with non-TKD mutations. They also had lower tumor mutational burden.<br /><br />Regarding treatment, 55.8% of patients received platinum-based chemotherapy alone or with immunotherapy as first-line treatment. The median real-world overall survival (rwOS) for first-line treatment was 14.7 months. Among patients treated with second-line therapies, 22.6% received platinum or platinum-based immunotherapy. The median rwOS and rwPFS for second-line treatment were 10.1 months and 3.2 months, respectively.<br /><br />The most common HER2 variant observed was A775_G776insYVMA. This study provides valuable insights into the epidemiology and outcomes of patients with HER2-mutated NSCLC, and contributes to the understanding of the tumor biology of this subgroup of patients. Overall, the study highlights the need for effective therapies for patients with NSCLC and HER2 mutations.

Keywords

advanced non-small cell lung cancer

HER2 mutations

Flatiron Health-Foundation Medicine

tyrosine kinase domain

tumor mutational burden

platinum-based chemotherapy

immunotherapy

overall survival

second-line therapies

HER2 variant